Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CGT6297 |
| Synonyms | |
| Therapy Description |
CGT6297 is a mutant-selective PIK3CA H1047R inhibitor (Cancer Res (2025) 85 (8_Supplement_1): 3004). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CGT6297 | CGT-6297|CGT 6297 | PIK3CA inhibitor 28 | CGT6297 is a mutant-selective PIK3CA H1047R inhibitor (Cancer Res (2025) 85 (8_Supplement_1): 3004). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07383506 | Phase I | CGT6297 | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors | Not yet recruiting | USA | 0 |